Investigator's Brochure (IB) Table
Drugs
| Drug Name Sort descending | Drug Company | IB Date | Risk List Available? |
|---|---|---|---|
| ABT-267, ABT 333, ABT-450 and Ritonavir | AbbVie | June 2017 | |
| Bedaquiline (TMC207) | Janssen Research & Development | October 2019 | |
| Cemiplimab (REGN2810) | Regeneron Pharmaceuticals, Inc. | September 2021 | |
| Cenicriviroc Mesylate CVC (TBR-652) | Allergan | April 2022 | |
| Dapivirine (Vaginal Ring) | International Partnership For Microbicides | September 2021 | |
| Delamanid (OPC-67683) | Otsuka | June 2021 | |
| Dolutegravir (GSK1349572) | ViiV Healthcare | October 2022 | |
| Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) | Merck | July 2021 | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) | Gilead Sciences | December 2016 | YES |
| Glecaprevir (ABT-493) and Pibrentasvir (ABT-530) | AbbVie | December 2018 | |
| GSK1265744 (Cabotegravir) | ViiV Healthcare | January 2023 | |
| Letermovir | Merck | October 2021 | |
| Pretomanid (PA-824) | Global Alliance for TB Drug Development (TB Alliance) | January 2023 | |
| Raltegravir (Isentress) | Merck | September 2017 | YES |
| Remdesivir (Veklury) | Gilead Sciences | June 2021 | |
| Rilpivirine (TMC278, Edurant) | Janssen Research & Development | July 2022 | |
| Sofosbuvir/Velapatasvir (Epclusa) | Gilead | July 2016 | |
| Tecovirimat (TPOXX) | SIGA Technologies, Inc. | December 2022 | |
| Tenofovir Alafenamide/Elvitegravir | CONRAD | July 2019 | |
| Vorinostat (Zolinza) | Merck | August 2013 |
Vaccines
| Vaccine Name Sort descending | Vaccine Company | IB Date | Risk List Available? |
|---|---|---|---|
| 10-1074 | Rockefeller University/Mass Biologics | September 2020 | |
| 10-1074-LS | Rockefeller University | October 2021 | |
| 16055 NFL Delta Gly4 Env Protein Trimer, Adjuvanted with 3M-052 AF + Alum | DAIDS/NIAID/NIH | December 2022 | |
| 3BNC117-LS | Rockefeller University | October 2021 | |
| 426c.Mod.Core-C4b, Adjuvanted - New - New | DAIDS/NIAID/NIH | April 2023 | |
| AdC6-HIVgp140, AdC7-HIVgp140, CH505TF/GLA-SE Vaccines | DAIDS/NIAID/NIH | March 2021 | |
| BG505 SOSIP.664 gp140 | DAIDS/NIAID/NIH | January 2023 | |
| CH505 TF chTrimer - New - New | DAIDS/NIAID/NIH | February 2023 | |
| ChAdOx1.HIVconsv62 - New - New | University of Oxford | April 2023 | |
| ChAdOx1.tHIVconsv1 | University of Oxford | December 2022 | |
| CMV-MVA Triplex | City of Hope National Medical Center | June 2022 | |
| EnvSeq-1 and EnvSeq-2 | DAIDS/NIAID/NIH | October 2022 | |
| GLA-SE | Infectious Disease Research Institute (IDRI) | November 2021 | |
| Hepatitis B Vaccine Recombinant, Adjuvanted (Heplisav-B) | Dynavax Technologies Corporation | September 2021 | |
| HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines (Ad4-Env150KN and Ad4-Env145NFL) | VRC/NIAID/NIH | July 2021 | |
| INO-6160 and INO-6172 | DAIDS/NIAID/NIH | January 2023 | |
| MPER-656 Liposomes with Aluminum Hydroxide Suspension | DAIDS/NIAID/NIH | February 2019 | |
| mRNA-1273 | ModernaTX | December 2020 | |
| mRNA-1574 Trimer Vaccines | DAIDS/NIAID/NIH | June 2022 | |
| MVA-CMDR | Walter Reed Army Institute Research (WRAIR) | November 2019 |